ismagilov
- Clinical-stage biopharmaceutical company Alumis (NASDAQ:ALMS) is having a rough day on its first day of trading with shares trading well below its IPO price of $16/share.
- As of 130p ET, shares were trading at $12.50, an almost 22% decline from its IPO price.
- Although the IPO was priced at $16, when the stock began trading shortly after 1230p, it opened at $13.48.